SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " genome " 92 found 🔀 AI-powered Shuffle
Verily Health to Integrate PacBio HiFi Sequencing With Data Platform
The multi-year collaboration will link PacBio sequencing workflows to Verily Pre to support biomedical research and AI model training.
M42 CEO on AI, genomics and the future of healthcare
M42 Group CEO Dimitris Moulavasilis discusses how the Abu Dhabi-based healthcare company is combining artificial intelligence, genomics and clinical services to reshape healthcare. He explores the group’s international expansion, the Emirati Genome Programme and the potential for technology to help doctors identify health risks earlier and move healthcare towards prevention rather than treatment.
Scientists Kept Finding The Same Mysterious DNA In Their Samples. The Marine Microbe It Belongs To Has The Smallest Genome Ever Identified
This tiny marine organism may demonstrate just how little genetic material a cell needs to survive.
Labcorp to Acquire Select Assets of BioReference Health for $722M
Labcorp will acquire BioReference's lab businesses focused on clinical and women's health testing, urology, and corrections as well as its 4Kscore prostate cancer blood test.
GenomeWeb Best Places to Work Winner (101-250 Employees): Health Advances
Life science consulting company Health Advances has won GenomeWeb's Best Places to Work award in the 101-250 employee category.
GenomeWeb Best Places to Work Winner (26-50 Employees): Genomate Health
Genomate Health, a Cambridge-based computational oncology company, has won GenomeWeb's Best Places to Work award in the 26-50 employee category for the second consecutive year.
10 years of Jackson Lab science shows the lifesaving power of genome-matched cancer treatment
These treatments have already changed the lives of Mainers battling the disease. Thankfully, more work lies ahead.
Danaher, Nvidia Ink AI-Driven Science Automation Collaboration
The firms will develop iterative automated solutions enabling artificial intelligence-guided scientific research.
Microbe Discovered With One of The Smallest Genomes on Record, Pushing The Bounds of What It Means to Be Alive
What is an organism, anyway?
African genomics research is growing: What countries are doing to connect genetic data and health care
Much of what scientists know about how genetic differences affect health comes from studying populations outside Africa. This matters because genetic information is increasingly being used to understand ...
Jonathan the Giant Tortoise Is 194 Years Old. He Just Had His Genome Sequenced.
Scientists have sequenced his genome for the first time, hoping the world’s oldest land animal can offer clues into the genetics of longevity.
Science highlights six landmark DNA and Human Genome Project breakthroughs that missed the Nobel Prize
From Avery’s genetic material discovery to the Human Genome Project’s 3 billion base pairs, major life-science advances faced Nobel limits on co-authorship and timing
Yale School of Medicine On the Science of Childhood Anxiety, Say, Anxiety Disorders Are the Most Common Mental Health Challenges In Youth
Credit: Matt Bradbury October 5, 2026 - By Isabella Backman - Anxiety disorders are the most common mental health challenges in youth. Left untreated, they can disrupt the lives of both children and their families. The good news is that with intervention, most children will overcome these conditions. Across Yale School of Medicine, scientists are working to understand anxiety at every level, from common anxious behaviors to molecular biomarkers in the brain. They are using their findings to develop and disseminate new evidence-based treatments for childhood anxiety. Today, the go-to treatment for childhood anxiety disorders is cognitive behavioral therapy (CBT). This is a form of psychotherapy that teaches children skills for confronting anxious thoughts and helps them practice managing situations that cause anxiety. While it is the gold-standard treatment backed by considerable scientific evidence, up to 50% of children will not see sufficient benefit from CBT alone. Wendy Silverman, PhD, Alfred A. Messer Professor in the Child Study Center, co-directs the Anxiety and Mood Disorders Program alongside Eli Lebowitz, PhD, associate professor in the Child Study Center. One of their main interests is learning how to improve outcomes beyond CBT. “We’re developing cutting-edge, research-based knowledge that can reduce the suffering that anxiety causes children and their families,” says Silverman. Changing parent behavior YSM experts are investigating how to improve CBT outcomes for children by involving the parents. Silverman’s research has uncovered two main components of parent intervention that improve childhood anxiety: not enabling children to completely avoid the things that make them anxious and taking steps to enhance their autonomy. Parents may unintentionally reinforce their child’s anxiety by allowing them to avoid what makes them anxious. They also may unintentionally limit the children’s sense of autonomy by being overly intrusive. “One of the things that we take pride in is that we’ve focused on trying to understand what parents need to do, and to test our ideas and see if changing the parents’ behaviors is enhancing the effects of CBT,” Silverman says. “Our findings thus far suggest that they do." As much as CBT can be helpful, it can also be challenging to get one’s child to do the necessary steps for CBT to work. This is one important reason why Lebowitz created a novel intervention program for parents named Supportive Parenting for Anxious Childhood Emotions (SPACE). Existing intervention programs often teach parents to act as therapists for their child, such as training them on how to practice breathing exercises. “It makes sense, but this doesn’t work very well in practice,” says Lebowitz. “And part of the reason, I think, is that it’s not easy to get your kid to do things, especially if they’re not excited about doing it.” SPACE is unique because it focuses entirely on parent involvement and changing parental behavior—children are not involved in the sessions. For example, parents learn how to use supportive messages that convey confidence that their child can tolerate and manage distress. “It might sound like a parent saying to a child, ‘I get that this is really hard for you, but I know that you can handle it,’” Lebowitz says. The program also works with parents to identify the ways in which they are accommodating anxious behaviors. “We’ll pick one thing that parents are doing that is an accommodation and help them make a detailed plan for how they’re going to change that,” Lebowitz explains. Treating Anxiety in Children and Adolescents Much of the existing research on SPACE has focused on parents of children under age 14. Ongoing studies are now exploring its use with parents of older teens. “Both anxiety and accommodation can interfere with normative developmental shifts during the teen years, including increased autonomy and individuation from parents,” says Rebecca Etkin, PhD, associate research scientist in the Child Study Center. “In this sense, SPACE may be particularly well-suited for anxious teens and their parents. We want to see whether it is effective during this distinct developmental window.” Unfortunately, many families in need of CBT face barriers, including limited availability of services and geographic constraints. One way to improve access is digital interventions. Silverman and her team are developing an evidence-based digitized intervention program for parents that they can access directly from their computer or smart phone. “The work we’re doing will be one of the very few parent interventions that is digitized and importantly tested for effectiveness,” she says. Creating interventions for anxiety-related challenges Silverman and Lebowitz recently received a generous gift to develop and test other interventions that help parents reduce other child anxiety-related behavioral and emotional difficulties, such as restrictive eating and unexplained somatic symptoms. One of these projects in particular focuses on understanding the risks of social media and its potential benefits, including offering a sense of connection. “A lot of research has focused on the idea that social media is harmful and the less of it the better,” says Lebowitz. “But we actually see is that this is not quite right—there are negatives, but there are also positives. So, we’re trying to get a little bit more nuanced of a picture.” The team is working with teens with social anxiety and their parents over an extended period to better understand their social media habits and how their anxiety levels affect engagement with different platforms. The teens will answer questions sent to an app on their phones about mood and social media usage in an effort to capture emotional responses as they unfold. “We hope to develop interventions that can help make the best of social media while protecting against the more problematic effects,” Lebowitz says. The brain’s role in anxiety Researchers are also testing therapies to address anxiety at the neurological and molecular levels. In collaboration with Dylan Gee, PhD, professor of psychology in Yale's Faculty of Arts and Sciences, and Hilary Blumberg, MD, John and Hope Furth Professor of Psychiatric Neuroscience at Yale School of Medicine, Lebowitz and Silverman are using brain imaging to identify changes in a child’s brain before and after parents enroll in SPACE. In one study, children viewed anxiety-inducing images while undergoing magnetic resonance imaging (MRI); the researchers conducted scans with and without the children’s parents nearby. Before SPACE, children’s brains were better able to activate the regulatory circuitry needed to turn off an anxious response when their parents were nearby. But after SPACE, children could activate this circuitry even without the parent around. “As parents work on gradually reducing some of their accommodations, you can see a child get better at regulating their own fear system in the brain,” Lebowitz says. “It’s remarkable.” Research into the molecular underpinnings of anxiety can also inform new childhood anxiety treatments. In a recent study, Lebowitz, Silverman, and Flora Vaccarino, MD, Harris Professor in the Child Study Center, discovered that a protein known as fibroblast growth factor 2 (FGF2) could be protective from the toxic effects of stress. FGF2 levels in children and their parents were linked to the children’s risk of developing anxiety and depression, the study showed. The findings could help explain why some children who are exposed to early life trauma such as poverty or abuse are more prone to developing mental health disorders. And FGF2 could be a target for treatment. “This is very novel because it starts to give a clue to what is the molecular chain that connects those lived experiences to the actual psychological outcomes,” Lebowitz says. New ways to study and treat childhood anxiety Michael Crowley, PhD, associate professor in the Child Study Center, collaborates with Silverman and Lebowitz to study the role that attention plays in development and maintenance of childhood anxiety. There is a large body of research that shows that anxious children, like anxious adults, are prone to focus on threatening stimuli such as angry faces compared with neutral faces. This has led to innovative interventions that involve attention retraining. The idea is that if experts train children to look away from threatening stimuli, it may reduce their anxiety—especially children with social anxiety who are most prone to attend to threats. The researchers have just completed a clinical trial for attention retraining with 10- to 14-year-olds with social anxiety disorders and are currently analyzing the findings. Besides this innovative attention retraining research, as Crowly notes, “I like to design tasks that are engaging to kids,” Crowley says. “My goal is to assess something without the kids knowing what we are assessing.” With this goal in mind, Crowley has created a virtual game, named Boom, to study threat processing in children with anxiety disorders. The game is similar to that of hot potato—the child and three digital players take turns virtually passing a ball to each other’s gloves. At some point, the ball turns into a bomb, and as the bomb lands in each player’s glove, the outline of the glove turns yellow. The goal is to avoid having the bomb go off in your glove. What isn’t obvious is that the game is designed to measure different types of threatening stimuli, both ambiguous and direct. In the game, the direct threat occurs as the bomb is traveling towards your glove. The ambiguous threat is the yellow outlined glove as it is unknown where the bomb will travel next. While children play the game, Crowley’s team measures their brain activity using electroencephalography (EEG). The researchers have discovered that in kids with anxiety, the brain reacts more strongly to ambiguous threats than it does in their peers, but less strongly to direct threats. They believe that the initial abnormally large brain response to not knowing where the bomb is going impairs the brain's ability to properly respond when the threat is actually traveling the child’s way. “The brains of children with anxiety are unable to differentiate between threats you need to do something about and those that are not your problem.” Michael Crowley, PhD, develops innovative games for studying anxiety in children and adolescents.Credit: Matt Bradbury Based on these insights, Crowley hopes to study whether interventions like attention training could restore appropriate threat processing. Crowley’s team is also working on a test called the Balloon Risk Avoidance Task, which evaluates risk-taking and avoidance behaviors. It features a digital balloon that is full of air and about to burst. Kids have six seconds to let air out of the balloon. The more air they let out, the less risk they face that the balloon will pop. But at the same time, the balloon becomes less valuable as it deflates. “The more air you keep in the balloon, the more points you get,” Crowley explains. So far, the researchers have found that when the balloons pop unexpectedly, teens with social anxiety show distinct brain responses. Studying these responses can help psychologists understand the underlying pathways driving the various manifestations of anxiety. The genetics of anxiety When Thomas Fernandez, MD, associate professor in the Child Study Center and of psychiatry, was still in training, there was a lot of excitement about understanding the genetics associated with autism spectrum disorder. Since then, scientists have identified around 250 genes associated with autism. The genetic contribution to anxiety disorders, on the other hand, has historically received less attention. Anxiety is less heritable than autism, but the genetic contribution for anxiety disorders that emerge in childhood may be higher than for anxiety disorders overall. While scientists estimate the heritability of anxiety disorders in general to be around 30% to 50%, some studies suggest higher heritability for certain childhood-onset anxiety presentations. “I saw firsthand how researchers in the field went about finding vulnerability genes for autism,” Fernandez says. “So, we’re using a very similar playbook for childhood anxiety.” “I saw firsthand how researchers in the field went about finding vulnerability genes for autism. So, we’re using a very similar playbook for childhood anxiety.” Thomas Fernandez, MD Associate Professor In the Child Study Center and in Psychiatry Now, Fernandez and Emily Olfson, MD, PhD, assistant professor in the Child Study Center, are studying children and their parents to identify genetic changes that are present in the child but not the parents, known as “de novo mutations.” “All of us have some de novo mutations—maybe about 50 to 100 sprinkled throughout the genome,” Olfson says. “But when they occur within the coding regions of genes, they can be really disruptive.” Previous research shows that people with autism have higher rates of damaging de novo mutations than the general population. In 2022, Olfson, Lebowitz, Silverman, and Fernandez published a study on 68 children and their families that found that children with anxiety had similarly high levels of these mutations. Studying de novo mutations can help point the researchers to where they should be looking for genes associated with anxiety. “The end game is using the genes to steer us toward the right part of biology that we can then target to come up with better treatments,” Fernandez says. Building on those findings, the team is now studying more families to better understand how these de novo mutations, along with other genetic and environmental factors, shape pediatric anxiety disorders. They recently received a National Institutes of Health grant to enroll 750 new families over the next five years. Olfson is the principal investigator, with co-investigators Lebowitz, Fernandez, Silverman, and Shuangge Steven Ma, PhD, department chair and professor of biostatistics at Yale School of Public Health. Neurodevelopment, Risk Genes, and Mental Health Conditions - The Olfson Lab Joel Gelernter, MD, Foundations Fund Professor of Psychiatry, is interested in how different anxiety disorders differ genomically. “We are studying social phobia, panic disorder, and generalized anxiety disorder, working to understand why people differ in their risk to these specific anxiety disorders and evaluating various risk factors,” he says. Gelernter was recently involved in one of the largest studies to date of the genomics underlying anxiety disorder. The study included around 122,000 people with anxiety disorders and around 730,000 without. It found that some genetic differences associated with anxiety were linked to signaling that helps reduce overactivity in the nervous system. Many anxiety medications available today work by targeting this process. “It’s nice when the biology that you get out of a large genome-wide study ratifies things that we already know because that can help increase confidence in further findings from the study,” Gelernter says. Uncovering the neurobiology of psychiatric disorders John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and chair of the Department of Psychiatry, is interested in the neurobiology of psychiatric disorders, including post-traumatic stress disorder (PTSD), of which anxiety is a major symptom. In the late 1980s, Krystal’s team discovered that the drug yohimbine activated symptoms in patients with PTSD. “This was the first time we could link a specific biological mechanism to the symptoms of PTSD,” Krystal says. At the time, he adds, this finding was highly controversial. “A lot of people felt that PTSD was a purely psychological syndrome that didn’t have an underlying biology.” Since then, Krystal has dived deep into understanding the neurobiology of PTSD to learn how to better treat it. His team is evaluating the use of ketamine and psychedelics. These would be among the first treatments to be developed specifically for PTSD. They may also be applicable for other disorders including anxiety disorders, Krystal adds. An important gap in PTSD treatment is the absence of biological tests that inform how to best help patients manage their PTSD symptoms. A doctor doesn’t diagnose cancer based on how they feel. Rather, they use tests of the biology of the cancer to determine the best course of treatment. “And we can’t do that in any psychiatric disorder other than Alzheimer’s disease,” Krystal says. “But now we are building a foundation for this approach to the treatment of anxiety disorders for the first time.” Source: Yale School of Medicine
NSF backs research collaboration to sequence Antarctic genomes
The National Science Foundation (NSF) has awarded $18.4 million to a group of scientists producing an extensive genetic database of Antarctic lifeforms. More than 250 Antarctic species’ genomes will
Scientists Simulated Microgravity in Human Cells and Found Something Unexpected About DNA
Simulated microgravity changed the nucleus but left the genome surprisingly intact.
Something Took Wing in Paleocene Sunsets
More than 56 million years ago, something took wing. Now, combining ancient fossils with genomes from living species, researchers are rewriting the bat family tree, and tracing these creatures toward their mysterious beginnings in Paleocene Europe.
Study reveals evolutionary history of bats, dating back 65 million years
Researchers assembled the largest collection of high-quality bat genomes to date
Scientists Uncover Gravity’s Impact on the Human Genome
Researchers build microgravity simulator to illuminate how external forces affect our cells
Earth's first bats didn't come from where we thought, landmark genetic study reveals
In the largest study of its kind to date, researchers compiled data from 103 bat genomes and 44 fossils to rewrite the bat family tree and determine where these animals first evolved.
New Study Illuminates Bats’ Murky Origins
The largest analysis of bat genomes and fossils suggests that the first bats emerged in Europe roughly 65 million years ago and that echolocation evolved early.
Google DeepMind's latest AI tool promises a new era for genetics research, but experts warn to take its predictions with caution
AlphaGenome Atlas could make it easier for geneticists to access powerful AI, but its predictions aren't always accurate.
A 3,700-Year-Old Virus Hiding in a Medieval Book Just Killed 500,000 Animals
Holy manuscripts preserved the genome of a plague that wiped out up to 90% of Europe’s historical sheep herds.
It took 3.7 billion years for this genome to evolve. UF students assembled it in one semester
Key points Eleven undergraduate students at the University of Florida are the first to assemble the pignut hickory tree genome. The work was done as part of a hands-on research course open to all majors and taught by instructors at the Florida Museum of Natural History. The hickory tree s
Scientists discover a major brain shift between ages 50 and 75
Scientists have uncovered sweeping changes in how the human brain controls and organizes its genome beginning in midlife, offering new clues to why aging sharply increases the risk of Alzheimer’s and other neurodegenerative diseases. One of the biggest shifts occurred between about ages 50 and 75, when many of the brain’s original immune cells declined and were replaced by cells with more inflammatory characteristics. Researchers also found weakening of cells that help maintain the blood-brain barrier, along with widespread deterioration in the genome’s three-dimensional organization.
DRC’s Ebola Lessons: Learned And Unlearned (Part I)
The lethality of the Ebola outbreak in the Democratic Republic of Congo (DRC) is not just in its genome. Neither is it entirely explained by the country’s
Scientists find a new layer of Alzheimer’s hidden in the genome
Scientists found that the 3D organization of DNA is disrupted in several types of brain cells affected by Alzheimer’s disease, altering how important genes are switched on and off. The discovery reveals a previously underexplored layer of the disease that could open new paths for understanding and eventually treating Alzheimer’s.
Spiraea genome reveals how Rosaceae evolved a key defense hormone
A chromosome-level genome of Chinese spiraea reveals how the rose family conserved and remodeled a major route for producing salicylic acid, a hormone central to plant immunity and environmental stress responses.
Google DeepMind’s AlphaGenome Takes Aim at One of Genetics’ Biggest Problems
Google DeepMind has released a huge new dataset that could make it easier for scientists to study how changes in our DNA affect the way the body works. Called AlphaGenome Atlas, it contains predictions for more than 9 billion possible single-letter changes in the human genome. The dataset is about one petabyte in size and […]
Prof Elizabeth Streicher unravels the science behind drug-resistant TB
Prof Elizabeth Streicher of the Division of Molecular Biology and Human Genetics delivered her inaugural lecture on Tuesday 1 September 2026. Her research focuses on the transmission and spread of Tuberculosis (TB). Knowing where TB transmission is happening can help to stop it from spreading. Prof Elizabeth Streicher of the Division of Molecular Biology and Human Genetics in the Faculty of Medicine and Health Sciences delivered her inaugural lecture on Tuesday 1 September 2026. The title of her lecture was Decoding tuberculosis: the evolution of technology, epidemiology and the Mycobacterium tuberculosis genome. Streicher explained to Corporate Communication and Marketing how molecular epidemiology (using genetic information to track how and why diseases spread through populations) has improved our understanding of where drug-resistant TB comes from, how it spreads and how drug resistance evolves within and between populations. Tell us more about your research and why you became interested in this specific field. Overall, our research group studies the genome (complete set of DNA instructions found in a cell) of Mycobacterium tuberculosis, the bacteria that cause tuberculosis (TB) disease. Various regions of the genome are interrogated to study different aspects of the disease. My main focus has been on the epidemiology of tuberculosis – how the bacteria’s genome changes over time and what this tells us about the transmission and spread of the disease. How would you describe the relevance of your work? If we understand how the bacteria that cause TB change and spread, it can assist in combating TB globally. How has molecular epidemiology helped improve our understanding of drug-resistant TB? Molecular epidemiology was very important in drug-resistant TB as it was originally believed that bacteria that become resistant to antibiotics would be less fit and not be able to transmit. But it was shown that they can transmit, and therefore have to be monitored to identify hotspots of transmission and outbreaks, etc. Can you tell us briefly about the spoligotyping technique and its advantages for studying drug-resistant TB? Spoligotyping (a molecular technique used to identify and track specific strains of TB bacteria) does not detect drug resistance, but since the technique is relatively quick to do, it can be very useful in real-time situations, e.g. to monitor outbreaks of drug resistance. Why are interrupting transmission chains and identifying genomic hotspots important for controlling the spread of TB? Knowing where TB transmission is happening can assist in allocating resources to those areas to stop future transmission and spread of TB. Higher education can be challenging. What keeps you motivated when things get tough? Students – how they are so passionate and dedicated to learning and contributing to research and society as a whole. What aspects of your work do you enjoy the most? Again, the students and colleagues! But also the fact that it is continuously changing and thereby we are learning and expanding our knowledge. In the end, I know that we contribute to a better society in our small way. Tell us something exciting about yourself that people would not expect. Even though I love hiking (day and multi-day hikes) and being outside, I really do not like camping! How do you spend your free time? I love hiking (wellbeing in nature) and like to watch most sports. ©Higher Education Media Services. Subscribe
Scientists Find More Than 1,000 DNA Variants Linked to Personality Traits
More than one million genomes helped identify DNA variants linked to extroversion, agreeableness, neuroticism and more. Researchers measured how those traits influenced how people lived.
Genome Duplication Is a Radical Evolutionary Gamble
By doubling their entire genome, organisms can evolve extremely rapidly — or they can lose it all. New studies reveal how to survive the high-risk, high-reward evolutionary event.
Scientists Found 6,000-Year-Old Human Remains. No Other People Share Their DNA.
If they have no ancestors or descendants, then who are they?
Researchers identify traces of two ‘ghost’ ancestors in modern human DNA
Scientists uncovered DNA from two mysterious human ancestors hidden in modern genomes, revealing new clues about our evolutionary past.
Scientists find hidden “highways” guiding animal evolution
A sweeping analysis of thousands of animal genomes suggests that chromosomes do not evolve randomly but instead follow a limited number of irreversible “evolutionary highways.” These one-way genetic changes preserve clues to more than 600 million years of animal history and could even help researchers explore where evolution may head next.
Mule helps scientists build the clearest horse and donkey genomes yet
A mule has helped researchers build the most complete reference genomes to date for horses and donkeys, giving scientists access to complex regions of DNA that earlier versions could not fully capture.
Government Science Websites Shouldn’t Apologize for Scientists
The job of a government science website is to inform the public about what science has discovered, not to pass judgment on historical figures for their alleged failure to live up to contemporary progressive standards of opinion. Someone should make that distinction clear to the men and women at the National Human Genome Research Institute (NHGRI).
AI needs science’s search history
“Actually, that’s where the gold is,” said Alasdair Russell, my graduate school friend who leads a pre-clinical genome editing group at Cambridge. He was talking about the winding road of science that is omitted from published papers. “When you’re discussing how to do the experiment, and why this way is better than another way, and what does the data really mean? I know what it shows, but what does it mean?” At RAAIS 2026, he described how his group has begun logging the twisting path of discovery as it happens, recording the verbal and written exchanges that normally disappear. Ideas become nodes in a living graph: they branch when a meeting produces two plausible experiments, merge when separate lines of evidence converge, and go dark when someone quietly stops pursuing them. In his implementation, one agent scores novelty, while another tries to learn “how scientists think and how they navigate through a complex world of data,” so that high-potential nodes can trigger deeper investigation. As frontier AI labs deploy agents toward scientific discovery, giving AI authentic scientific taste remains a trillion-dollar dilemma. The bottleneck is that the record we have kept for centuries of science might be insufficient to get us there. The experiments that never make the paper Peter Medawar, 1960 Nobel laureate and “father of transplantation,” asked in 1963 whether the scientific paper was a fraud, and answered yes: the form of the paper misrepresents the thinking that produced it. Sixty years on, the diagnosis is unchanged. A paper presents a clean progression from hypothesis to result to conclusion. Lost along the way are the unconventional theories, the abandoned or unaffordable methods, and the underwhelming and inconclusive data. It reads like a browser history with every dead end deleted: the ten open tabs, the four rephrased queries, the wrong turn down a subforum. All scrubbed, leaving one clean path from question to answer as the canonical path. What has changed since then is that the discarded material is now worth something. No high-impact journal wants these artifacts, but raw trial and error is the most likely source of the training data required to develop scientific intuition, or what researchers call taste. Earlier attempts to capture the discards were motivated by scientific integrity. The Journal of Negative Results in Biomedicine launched in 2002 to publish rigorous studies that disputed established models or exposed ineffective treatments. Its archive preserved negative conclusions after they had become papers, rather than the live alternatives and arguments that produced them. BioMed Central closed it in 2017, saying the mission had been served now that other journals publish null results. A less generous reading is that in fifteen years it published around 200 papers because almost nobody wants to read a negative result, let alone write one up when it will not count toward academic tenure. AI models are different. Even an uninteresting negative result can be useful, provided it is labeled. Earlier this year, Anthropic put a version of this to the test. The company pulled 129 decision points from real Claude Code sessions between January and March 2026, showed models the work up to a human detour, and asked what should happen next. Claude Mythos Preview beat the human choice 64% of the time, while Opus 4.5 managed 51%. The comparison was tilted toward the models because Anthropic deliberately chose moments where the human decision had room for improvement. On 127 further scenarios where the human action was already strong, the models improved on it only about 20% of the time. The study was possible because Anthropic’s researchers work inside a tool that logs by default. The reasoning, detours and outcome are produced in the same working environment. Biology has no equivalent. Its reasoning happens in hallways, at benches, in Slack threads and on whiteboards, while the outcome arrives weeks later somewhere else. The record has to emerge from the work itself. Ask scientists to reconstruct it afterwards and we’ll create another polished account. Subscribe A log is not a label Before any of this becomes training data, a negative result has to say what failed. The first paper published in the Journal of Negative Results in Biomedicine examined 234 negative studies across five leading medical journals. Only 30% discussed statistical power, and half clearly defined a primary outcome. Tell a model an experiment failed, without telling it whether the assay was underpowered, a reagent had degraded, or the hypothesis was simply wrong, and it will learn noise with confidence. Decision histories have a second missing label too. When a lab considers five experiments and runs one, only the chosen branch returns an outcome. The other four are experimental counterfactuals. Researchers call this the selective labels problem: the data reveal results only for the actions someone chose to take. Such a record can teach a model to imitate a lab’s taste, but it cannot establish that the taste was good. It also smuggles local constraints into general lessons. A lab that never ran cryo-EM because it did not own a microscope teaches a model that cryo-EM is rarely the right call. Alasdair’s nodes preserve the candidate set, which is the necessary first step. To be useful, each decision record needs six fields: The evidence available at that moment, and nothing that arrived later. The candidates considered, including the ones dismissed in a sentence. For each candidate: the expected result, the confidence attached to it, and the cost in time and money. The route chosen, and the reason. What happened next. How the evidence changed the scientist’s view. These must be timestamped before the outcome, because hindsight turns uncertainty into inevitability. Disagreement also has to survive. Averaging three scientists into one clean rationale reproduces exactly the information loss we are trying to fix. But there is an obvious failure mode here. Once decisions are logged and scored, people log for the record post-facto. Anyone who has watched an electronic lab notebook fill up with retrospective tidying knows how quickly a research tool becomes a compliance exercise. A record that costs a scientist ten minutes of honest reflection per decision is worth far more than one that costs an hour of performance. A publication initiative called Registered Reports offers a useful starting point. Here, researchers submit their rationale, methods and analysis plan for peer review before the data exist, and the journal commits in principle to publish if they follow the approved plan. Nature has now expanded the format across every field it covers. This approach to paper writing timestamps intent before the outcome, but it freezes one plan. A useful search history must also preserve how the plan changed, which alternatives were rejected, when, and on what evidence. Subscribe Run the runner-up Autonomous labs show what happens when decisions and outcomes are connected in a loop. Liverpool’s mobile robotic chemist ran 688 experiments over eight days in a ten-variable formulation space. A batched Bayesian search used each result to choose the next experiments and found photocatalyst mixtures six times more active than the starting formulations. Every completed experiment changed what the system did next. The robot optimized within a goal and search space that humans had already chosen. It did not decide which scientific question mattered. So what this work demonstrates is narrower, but still useful: a search history pays off when the options return standardized outcomes quickly. Open-ended biology is harder because branches can take weeks and the discarded alternatives may never be run. Some exploration therefore has to be bought. Where two branches are plausible and the stakes justify the cost, a lab should sometimes run the runner-up. Otherwise the record captures what today’s scientists usually chose and stays silent on what they systematically overlooked. A funder could ring-fence a small fraction of a grant for the branch not taken, provided that the decision record and the outcome are both deposited. That costs money, but so does having every lab rediscover the same abandoned path. Test whether taste transfers When it comes time to evaluate if our new AI system exhibits taste, the comparison should run across laboratories and fields. At selected decision points in a live research campaign, we should freeze the six fields: the evidence, the candidates, expected results, confidence, costs and the choice made. Experts then rank the options before the outcomes are known, and those outcomes are checked independently later. We could give models one of two diets - papers alone, or papers plus decision histories - and ask them to rank the next experiment on unfamiliar projects. Then, we score information gained per dollar and week, calibration, and how quickly weak branches are abandoned. If histories improve choices only inside the lab that produced them, they amount to useful organizational memory. If they improve choices on unfamiliar problems elsewhere, Alasdair’s group will have captured something science has never managed to write down: a transferable record of taste. Until that happens, a scientific search history is a promising record, not yet a training set.
AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The center will join...
Scientific advancement has never been more prolific—so why has trust in science plummeted?
From genome editing to quantum computing, scientific progress is accelerating at an unprecedented pace, yet public faith in science is collapsing. Our species has mapped the human genome, created powerful ...
UNC researchers are using Palantir to build a massive collection of health data
The data collected so far “includes more than 535,000 whole genome sequences.”
This A.I. Just Created Viruses Not Found in Nature
Scientists trained artificial intelligence on libraries of DNA and then asked the model to create recipes for viral genomes. Sixteen of them were viable, yielding new viruses.
AI designs a novel E. coli killer
Using an AI model of their own creation that writes whole genomes, a team of Stanford scientists has engineered a novel bacteria-fighting phage. A new age of antibiotics could be on the horizon.
Strange DNA Structures Found in The Human Genome Go Beyond The Double Helix
“We now have a complete picture."
Strange DNA Structures Found in The Human Genome Go Beyond The Double Helix
“We now have a complete picture."
Everyone alive may carry DNA from a ‘ghost lineage’ of human ancestors
Scientists analyzing modern genomes may have found a long-lost branch of the human family tree
Great Barrier Reef microbiome mapped as researchers discover 500 bacterial species previously unknown to science
Research identifies 808,585 viral genomes belonging to what scientists estimate to be 362,802 different viruses
Scientists say Beefalo are all beef, no -alo. Breeders disagree
A whole-genome analysis of Beefalo, a hybrid bison-cattle breed, suggests very few individuals have any bison DNA at all, a new study reports.
WHO says progress stalling on air pollution, and other health stories
Top stories: Air pollution progress stagnates - WHO; Ebola epidemic impacting livelihoods - UN; World's largest database of human genomes released.
N.I.H. Announces World’s Largest Integrated Health Database
It contains more than half a million people’s genomes, paired with clinical records and wearable tech data. That gives researchers unmatched power to study both diseases and treatments.
Supreme Court rules in weedkiller cancer case
Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
New DNA study of Neanderthals bolsters suspicions of human-driven extinction
Analysis of 27 genomes reveals more diverse, better-connected populations and challenges the idea that genetic decline caused their disappearance
Why South Africa’s leopards shrank to half their normal size
A hidden population of South African leopards has revealed a remarkable evolutionary story. Researchers analyzing entire leopard genomes discovered that the Cape Floristic Region’s leopards are not only much smaller than most African leopards, but also genetically distinct after being isolated for roughly 20,000 years. Surprisingly, despite their small population, they have retained much of their genetic diversity.
DNA time stamps reveal the strawberry’s surprising origins
Researchers have created a new way to reconstruct the evolutionary history of complex plant genomes by analyzing genetic traces left by transposable elements. The technique revealed that modern strawberries were assembled through multiple ancient genome-merging events, shedding new light on how major crop species evolved.
Testing longitudinal gene–environment interactions
Nature Computational Science - A gene–environment interaction test (SAGELD) is developed to speed up large-scale genome-wide analyses using longitudinal data, facilitating novel discoveries...
Ancient DNA shared with Neanderthals may explain human language
A tiny set of ancient genetic “switches” may have played a surprisingly large role in making human language possible. Researchers found that these DNA regions, which act like volume controls for genes involved in brain development, have an outsized influence on language ability despite making up less than 0.1% of the genome.
In a first, scientists translated an entire viral genome so a quantum computer could read and analyze it
Scientists have uploaded a viral genome to a quantum computer, marking an important step for the future of quantum-enabled advancements in biology.
Scientists Built a Tool to Predict When You’re Going to Die
Scientists are using the secrets of the genome to predict one of life’s most cryptic events.
Breeding Possibilities for Better Crops
Driven by a strong work ethic, Caitlin Kestell, a doctoral student in crop science, pursues genome editing and biotechnology to advance crop improvement and inspire young scientists.
Scientists Discover Over 1,700 'Dark' Proteins Hidden in Human Cells
A new layer of the human genome has been revealed.
Craig Venter obituary
Pioneering and controversial geneticist who was one of the first to sequence the human genome, in part by using his own DNA
Who are the Japanese? Huge DNA discovery rewrites history
Scientists analyzing the genomes of thousands of people across Japan discovered evidence for a previously overlooked third ancestral group, challenging the long-accepted “dual origins” theory. The newly identified ancestry appears linked to the ancient Emishi people of northeastern Japan. Researchers also uncovered inherited Neanderthal and Denisovan DNA connected to conditions like diabetes, heart disease, and cancer.
The National Academy of Sciences Elects Two Berkeley Lab Researchers
Two Lawrence Berkeley National Laboratory (Berkeley Lab) scientists have been elected to the National Academy of Sciences (NAS) in recognition of their distinguished and continuing achievements in original research. They are part of a cohort of 120 new members and 25 international members. The National Academy of Sciences is a private, nonprofit institution that was established under a congressional charter signed by President Abraham Lincoln in 1863. It recognizes achievement in science by election to membership, and — alongside the National Academy of Engineering and the National Academy of Medicine — provides science, engineering, and health policy advice to the federal government and other organizations. The 2026 electees bring the total number of active members to 2,705 with 557 international members. Gary Karpen is a biologist senior faculty scientist in Berkeley Lab’s Biological Systems and Engineering Division and a Professor of Cell and Developmental Physiology in the Department of Molecular and Cell Biology at UC Berkeley. Karpen studies how the structure, organization, and maintenance of genetic material impact inheritance and cell function. His lab focuses on chromatin — a packaged form of DNA strands wrapped around proteins that comprises our chromosomes — with a particular emphasis on centromeres, rarely expressed sequences called heterochromatin, DNA repair, and regulatory RNAs. His research reveals insights into fundamental aspects of nuclear organization and genome regulation that are shared across the tree of life, broadening our understanding of cancer and other diseases, birth defects, and aging. Kam-Biu Luk is a Professor Emeritus of physics at UC Berkeley and a retired senior faculty scientist in Berkeley Lab’s Physics Division. He is an experimental particle physicist whose research has focused on neutrinos: nearly massless, electrically neutral elementary particles that can pass through matter virtually undetected. Neutrinos are created during radioactive decay processes, including the fusion process occurring in stars and the fission process that powers nuclear reactors. Luk initiated and co-led the Daya Bay Reactor Neutrino Experiment, a project based in China with more than 200 international collaborators. In 2012, the Daya Bay experiment discovered a new form of a phenomenon called “neutrino oscillation” in which neutrinos change from one type to another. For this discovery, Luk and his collaborator Yifan Wang received the 2014 American Physical Society Division of Particles and Fields W.K.H. Panofsky Prize for outstanding work in experimental particle physics, and he was also the co-recipient of the 2016 Breakthrough Prize. Luk is currently participating in the Deep Underground Neutrino Experiment (DUNE) hosted by Fermi National Accelerator Laboratory, which will investigate any potential difference in behavior between neutrinos and antineutrinos that may shed light on the evolution of the universe, especially why antimatter is absent in the present universe. ### Lawrence Berkeley National Laboratory (Berkeley Lab) is committed to groundbreaking research focused on discovery science and solutions for abundant and reliable energy supplies. The lab’s expertise spans materials, chemistry, physics, biology, earth and environmental science, mathematics, and computing. Researchers from around the world rely on the lab’s world-class scientific facilities for their own pioneering research. Founded in 1931 on the belief that the biggest problems are best addressed by teams, Berkeley Lab and its scientists have been recognized with 17 Nobel Prizes. Berkeley Lab is a multiprogram national laboratory managed by the University of California for the U.S. Department of Energy’s Office of Science. DOE’s Office of Science is the single largest supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visit energy.gov/science.
J. Craig Venter, Scientist Who Decoded the Human Genome, Dies at 79
A risk-taking outsider, he brought speed, competition and controversy to one of science’s biggest races.
DNA study of nearly 200 Indigenous genomes reveals unknown Asian 'ghost' population contributed to American ancestry
New genetic results reveal a previously unknown wave of people settled in South America 1,300 years ago and that Indigenous Americans carry remnants of a "ghost lineage."
1000 new African genomes added to global science
Wits-led AGenDA project sequenced 1,000+ African genomes, uncovering vast genetic diversity and novel variants. This helps correct Eurocentric bias in global datasets, improving disease prediction, treatment design, and ensuring African populations benefit from genomic medicine.
How squid survived Earth’s biggest extinction and took over the oceans
Scientists have finally cracked a long-standing mystery about squid and cuttlefish evolution by analyzing newly sequenced genomes alongside global datasets. The research reveals that these bizarre, intelligent creatures likely originated deep in the ocean over 100 million years ago, surviving mass extinction events by retreating into oxygen-rich deep-sea refuges. For millions of years, their evolution barely changed—until a dramatic post-extinction boom sparked rapid diversification as they moved into new shallow-water habitats.
Decapodiform evolutionary tree
The researchers employed multiple decapodiformes genomes along with a robust model of evolution and fossil evidence. Their evolutionary tree branches into 4 sections in the Cretaceous period, then sees no further branching until after the K-Pg extinction event, when rapid diversification occurred. Each final line end marks a different species. Of the major orders of decapodiformes, just oegopsida and spirulida remain in the deep ocean habitats of their ancestors.
Ingredion and Holobiome map gut microbiome to unlock targeted health benefits
Ingredion has partnered with Holobiome to use AI and its database of two million bacterial genomes to predict how specific ingredients will interact with human health before clinical trials. The research expands beyond digestion to explore how sweeteners, plant proteins, and texture solutions influence the gut-brain axis, including sleep and mental health.
David Botstein, Gene-Mapping Pioneer, Dies at 83
His method of locating genes in human DNA allowed researchers to find disease-causing genes, and later to map the entire, sprawling human genome.
Scientists Don’t Know Exactly What a Shark Is
A new study analyzing the genomes of nearly 40 sharks found that skates and rays likely evolved from the shark body plan, and that some sharks are actually evolutionarily distinct.
Scientists discover ancient DNA “switches” hidden in plants for 400 million years
Scientists have uncovered an enormous hidden archive of plant DNA that has endured for more than 400 million years. By comparing hundreds of plant genomes, researchers identified more than 2.3 million regulatory DNA sequences that act like genetic switches, controlling when and how genes are activated. These sequences, known as conserved non-coding sequences (CNSs), were detected using a new computational tool called Conservatory.
Around the MHS
The latest news from around the Military Health System for the week of March 2-6, 2026, includes a vital collaboration between Department of War and the Department of Veterans Affairs, new whole genome sequencing brain research, and a military surgical milestone.
Scientists Found 6,000-Year-Old Human Remains. No Other People Share Their DNA.
If they have no ancestors or descendants, then who are they?
What Your DNA Reveals About the Sex Life of Neanderthals
Most people alive today carry fragments of Neanderthal DNA in their genome. Now scientists are gaining a more intimate understanding of the ancient encounters that put it there.
Reading the enemy: How genome science is reshaping the fight against wheat stem rust
In 2013, farmers in the highlands of Ethiopia began to notice something unsettling: a familiar variety of wheat was failing in an unfamiliar way. Stems weakened, plants collapsed, and fields that had ...
Genome Science Revolutionizes Wheat Stem Rust Battle
Key points Genome sequencing of several wheat stem rust strains shows some outbreaks arose independently, overturning assumptions and changing how
Scientists uncover oxygen-loving ancestor of all complex life
For decades, scientists have believed that complex life began when two very different microbes joined forces, eventually giving rise to plants, animals, and fungi. But one major puzzle remained: how could these organisms have met if one depended on oxygen and the other supposedly lived without it? New research suggests the answer lies in ancient microbes called Asgard archaea.
All Life on Earth Has One Common Ancestor. Scientists Think These Genes Predate It.
Scientists think they’ve found a way to investigate the creation of cell membranes and DNA genomes that gave rise to the last universal common ancestor.
The Human Exposome Project will map how environmental factors shape health
It makes the Human Genome Project look easy
Google DeepMind launches AI tool to help identify genetic drivers of disease
AlphaGenome can analyse up to 1m letters of DNA code at once and could pave way for new treatments
Google DeepMind launches AI tool to help identify genetic drivers of disease
AlphaGenome can analyse up to 1m letters of DNA code at once and could pave way for new treatments
With AlphaGenome, Researchers Are Using A.I. to Decode the Human Blueprint
AlphaGenome is a leap forward in the ability to study the human blueprint. But the fine workings of our DNA are still largely a mystery.
Project adds more than 1,000 new African genomes to global science
A newly published paper in Nature describes the complex process of launching a nine-country collaboration in Africa to significantly expand scientists' understanding of human genetic diversity. This can ...
In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
From the 14,000-year-old chunk of preserved woolly rhinoceros meat, researchers were able to sequence the creature's full genome.
What a Wolf Pup’s Stomach Revealed About the Woolly Rhino’s Extinction
Scientists prepared a high-quality sequence of the giant mammal’s genome based on a specimen preserved in Siberian permafrost.
Decoding the perfect steak: The hidden DNA behind Wagyu’s legendary marbling
A groundbreaking cattle genome has given researchers their clearest look yet at what makes Wagyu beef so special. By uncovering hundreds of new genes and hidden genetic variations, scientists can now pinpoint traits linked to marbling, health, and productivity with far greater accuracy. The advance could boost profits for beef producers while improving breeding outcomes across many cattle breeds. It also sets the stage for even more comprehensive livestock genomes in the future.
Racing against time: Inside a Nahant genome bank’s bid to save marine diversity before it’s lost
The Ocean Genome Legacy Center and other biorepositories like it are increasingly crucial to climate change research as global warming threatens marine species.
The biggest scientific breakthroughs of the last 25 years—and a few to watch
From decoding the human genome to exploring the universe, science has made huge strides in the 21st century.
Scientists finally sequence the vampire squid's huge genome, revealing secrets of the 'living fossil'
The genetic link between squids and octopuses may just be found in the vampire squid genome.
'An extreme end of human genetic variation': Ancient humans were isolated in southern Africa for nearly 100,000 years, and their genetics are stunningly different
Ancient genomes from southern Africa show that people evolved in isolation for upward of 100,000 years.